Seoul, South Korea

Young Key Shin

This inventor holds 1 USPTO granted patent. Top assignees: Abion Inc., Seoul National University. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Young Key Shin. Retrieved from https://idiyas.com/inventor/young-key-shin-mu476res

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Young Key Shin: Innovator in mRNA Technology

Introduction

Young Key Shin is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of mRNA technology. His innovative work has the potential to impact various medical applications.

Latest Patents

Young Key Shin holds a patent for an invention titled "In-Vitro Transcript mRNA and Pharmaceutical Composition Comprising Same." This patent showcases his expertise in creating pharmaceutical compositions that utilize mRNA technology, which is crucial for advancing therapeutic solutions.

Career Highlights

Throughout his career, Young Key Shin has worked with notable organizations, including Abion Inc. and Seoul National University. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Due to space constraints, the collaborations section will be omitted.

Conclusion

Young Key Shin's contributions to mRNA technology and his innovative spirit make him a noteworthy figure in the field of biotechnology. His work continues to pave the way for future advancements in medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…